# US 2015/0148538 A1 · Use of an h4 agonist molecule to treat acute leukemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148538 A1
- Document ID: US20150148538A1
- Status: Published application
- Kind: A1
- Application number: 14/555,773
- Filed: 2014-11-28
- Published: 2015-05-28
- Earliest claimed: 2013-11-27
- Inventors: Gaetan TERRASSE
- Web page: https://patentgrep.com/patent/US20150148538A1

## CPC

- A61K 31/4741: condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- C07D 498/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to the use of new chemical substances, the levogyre and dextrogyre enantiomers of (AMINO-7 TRIETHOXY-4,5,6 OXO-1 DIHYDRO-1,3 ISOBENZOFURANNYL-3)-1 METHOXY-8 METHYL-2METHYLENEDIOXY-6,7 TETRAHYDRO-,2,3,4 ISOQUINOLEINE or tritoqualine, to treat acute myeloid or lymphoid leukemia, with the exception of type B leukemia.

## Claims

### Claim 1

A substance having an agonist activity on the histamine H4 receptor to treat acute myeloid leukemia and type T lymphoid leukemia, with the exception of type B leukemia, characterized in that it is made up of an isomer or an isomer mixture of AMINO-7 TRIETHOXY-4,5,6 OXO-1 DIHYDRO-1,3 ISOBENZOFURANNYL-3)-1METHOXY-8 METHYL-2METHYLENEDIOXY-6,7 TETRAHYDRO,2,3,4 ISOQUINOLEINE, or tritoqualine.

### Claim 2 (depends on 1)

The substance according to claim 1, characterized in that it inhibits the G0/G1 phase proliferation of myeloid leukemia cells and lymphoid cells, with the exception of type B leukemia cells, and in that it is non-toxic for normal hematopoietic stem cells.

### Claim 3 (depends on 1)

The substance according to claim 1, characterized in that it is packaged in doses from 100 to 2000 mg.

### Claim 4 (depends on 1)

The substance according to claim 1, characterized in that it is packaged in different galenic forms such as tablets, gel caps, gel, capsules, injectable solution.

### Claim 5 (depends on 2)

The substance according to claim 2, characterized in that it is packaged in doses from 100 to 2000 mg.
